Drug
Argx 117
Argx 117: highest development phase Phase 2, developed by Argenx. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-117 NCT05907096 | Phase 2 | Delayed Graft Function |
| ARGX-117 NCT05405361 | Phase 2 | Multifocal Motor Neuropathy (MMN) |
| ARGX-117 NCT05225675 | Phase 2 | Multifocal Motor Neuropathy |
| ARGX-117 NCT04532125 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Argx 117 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.